{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:57:11Z","timestamp":1771001831675,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UGC"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.compbiolchem.2017.11.005","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T10:45:50Z","timestamp":1510656350000},"page":"224-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach"],"prefix":"10.1016","volume":"71","author":[{"given":"Rohini","family":"Rondla","sequence":"first","affiliation":[]},{"given":"Lavanya Souda","family":"PadmaRao","sequence":"additional","affiliation":[]},{"given":"Vishwanath","family":"Ramatenki","sequence":"additional","affiliation":[]},{"given":"Aboubakr","family":"Haredi-Abdel-Monsef","sequence":"additional","affiliation":[]},{"given":"Sarita Rajender","family":"Potlapally","sequence":"additional","affiliation":[]},{"given":"Uma","family":"Vuruputuri","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1039\/b518019h","article-title":"Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin","volume":"4","author":"Aubry","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0025","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist\u2019s guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0030","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1016\/j.bmc.2008.04.048","article-title":"Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4\/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses","volume":"16","author":"Caballero","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/aps.2013.105","article-title":"3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis","volume":"35","author":"Cai","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0040","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1039\/C5MB00860C","article-title":"Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations","volume":"12","author":"Chohan","year":"2016","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","article-title":"CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced Breast cancer phase II activity, safety, and predictive biomarker assessment","volume":"21","author":"DeMichele","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0050","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejmech.2007.01.010","article-title":"3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors An insight into the criteria for selectivity","volume":"42","author":"Dessalew","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0055","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","article-title":"Molecular pathways: CDK4 inhibitors for cancer therapy","volume":"20","author":"Dickson","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ddtec.2013.02.002","article-title":"Combination of ligand- and structure-based methods in virtual screening","volume":"10","author":"Drwal","year":"2013","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0065","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide:A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treatment Rev."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0075","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/jm010326y","article-title":"A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues","volume":"44","author":"Honma","year":"2001","journal-title":"J. Med.Chem"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0080","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1021\/jm0608356","article-title":"Benchmarking sets for molecular docking","volume":"49","author":"Huang","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bioinformatics\/btp650","article-title":"Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis","volume":"26","author":"Huang","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0090","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/anie.200200540","article-title":"Small molecules as inhibitors of cyclin-dependent kinases","volume":"42","author":"Huwe","year":"2003","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0095","doi-asserted-by":"crossref","first-page":"27548","DOI":"10.1074\/jbc.M102060200","article-title":"Crystallographic approach to identification of cyclin-dependent kinase 4 CDK4.-specific inhibitors by using CDK4 mimic CDK2 protein","volume":"276","author":"Ikuta","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0100","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1016\/j.bmc.2008.07.002","article-title":"Design, synthesis and biological evaluation of new tryptamine and tetrahydro-\u03b2-carboline-based selective inhibitors of CDK4","volume":"16","author":"Jenkins","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/481455a","article-title":"Drug discovery: chemical beauty contest","volume":"481","author":"Leeson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2009.06.065","article-title":"Rational drug design","volume":"625","author":"Mandal","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0120","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.3390\/molecules190914366","article-title":"Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey","volume":"19","author":"Mariaule","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0125","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/ci400529h","article-title":"ZINClick: a database of 16 million novel, patentable, and readily synthesizable 1,4-disubstituted triazoles","volume":"54","author":"Massarotti","year":"2014","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.chembiol.2004.03.022","article-title":"Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors","volume":"11","author":"McInnes","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with Breast cancer, non\u2013small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jnci\/93.6.436","article-title":"Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4","volume":"93","author":"Rajeev","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrclinonc.2016.202","article-title":"Breast cancer PALOMA-2- hope beyond the threshold","volume":"14","author":"Romero","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0165","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molstruc.2016.12.106","article-title":"Azolium analogues as CDK4 inhibitors Pharmacophore modeling, 3D QSAR study and new lead drug discovery","volume":"1134","author":"Rondla","year":"2017","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0170","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1016\/j.bmcl.2015.05.100","article-title":"Cyclin dependent kinase CDK. inhibitors as anticancer drugs","volume":"25","author":"S\u00e1nchez-Mart\u00ednez","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0175","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0180","doi-asserted-by":"crossref","first-page":"42612","DOI":"10.1371\/journal.pone.0042612","article-title":"FASCAPLYSIN as a specific inhibitor for CDK4: insights from molecular modelling","volume":"7","author":"Shafiq","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6 from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0190","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ejmech.2006.06.010","article-title":"3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors","volume":"41","author":"Singh","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0200","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4155\/fmc.11.18","article-title":"Integrating structure-based and ligand-based approaches for computational drug design","volume":"3","author":"Wilson","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.11.005_bib0205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"van de Waterbeemd","year":"2003","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927117303304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927117303304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T00:09:02Z","timestamp":1570320542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927117303304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":41,"alternative-id":["S1476927117303304"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2017.11.005","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2017.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}